ClinicalTrials.gg
CompletedNCT05151731Updated May 11, 2026Results posted

A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema

A Phase 2 interventional study of Vamikibart and Ranibizumab in Diabetic Macular Edema, sponsored by Hoffmann-La Roche. Completed at 74 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
394
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Macular Edema by Hoffmann-La Roche — 1 open to participants now, 5 under way, 1 of them phase 3. Macular Edema · Hoffmann-La Roche.

Enrollment
9th of 25
394 · median 377
Started
2021
with 3 others
Phase 2
4 of 28
none open now
Registered
17th of 28
by date

Among the 28 studies in Macular Edema by Hoffmann-La Roche, this one is the 9th largest by enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2021, is one of 4 in phase 2, and was the 17th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 28 studies in Macular Edema by Hoffmann-La Roche is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Macular Edema by Hoffmann-La Roche, or all of them as a file.
02

Study summary

Study BP43445 is a phase II, multicenter, randomized, double-masked, active comparator-controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of vamikibart administered intravitreally in participants with diabetic macular edema. Only one eye will be chosen as the study eye. The duration of the study will be up to 76 weeks.

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of diabetes mellitus (Type 1 or Type 2)
  • Macular thickening secondary to diabetic macular edema (DME) involving the center of the macula
  • Decreased visual acuity attributable primarily to DME
  • Ability and willingness to provide written and to comply with the study protocol
  • Willingness to allow Aqueous Humor collection
  • For women of : agreement to remain abstinent or use at least one highly effective method that results in a failure rate of \<1% per year during the treatment period and for at least 12 weeks after the final dose of study treatment

Exclusion criteria

Exclusion Criteria:

  • (HbA1c) of greater than (>) 12%
  • Uncontrolled blood pressure, defined as a systolic value greater than (>)180 millimeters of mercury (mmHg) and/or a diastolic value >100 mmHg while a patient is at rest
  • Currently pregnant or breastfeeding, or intend to become pregnant during the study
  • Prior treatment with panretinal photocoagulation or macular laser to the study eye
  • Any intraocular or periocular treatment within the past 16 weeks prior to Day 1 to the study eye
  • Prior Iluvien or Retisert implants within 3 years prior to Day 1 to the study eye
  • Prior or concomitant treatment with anti-VEGF therapy within 8 weeks prior to Day 1 to the study eye; Vabysmo\^TM within 16 weeks prior to Day 1, prior Beovu® is not permitted
  • Prior administration of IVT brolucizumab (Beovu®): ever; vamikibart: \</=24 weeks prior to Day 1) in either eye
  • Any proliferative diabetic retinopathy
  • Active intraocular or periocular infection or active intraocular inflammation in the study eye
  • Any current or history of ocular disease other than DME that may confound assessment of the macula or affect central vision in the study eye
  • Any current ocular condition which, in the opinion of the investigator, is currently causing or could be expected to contribute to irreversible vision loss due to a cause other than DME in the study eye
  • Other protocol-specified inclusion/exclusion criteria may apply
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
394 participants (actual)

Study arms

  • Experimental
    Arm A: 0.25 mg Vamikibart Q8W

    Participants will receive vamikibart 0.25 milligrams (mg), by intravitreal (IVT) injection, on Day 1 and every 8th week (Q8W), up to Week 44, for a total of 6 injections. A sham procedure will be administered during study visits at which no study drug is administered to maintain masking between treatment arms.

    Drug: Vamikibart · Other: Sham Procedure

  • Experimental
    Arm B: 1.0 mg Vamikibart Q8W

    Participants will receive vamikibart 1.0 mg, by IVT injection, on Day 1 and Q8W, up to Week 44, for a total of 6 injections. A sham procedure will be administered during study visits at which no study drug is administered to maintain masking between treatment arms.

    Drug: Vamikibart · Other: Sham Procedure

  • Experimental
    Arm C: 1.0 mg Vamikibart Q4W

    Participants will receive vamikibart 1.0 mg, by IVT injection, on Day 1 and every 4th week (Q4W), up to Week 44 for a total of 12 injections.

    Drug: Vamikibart

  • Active comparator
    Arm D: 0.5 mg Ranibizumab Q4W

    Participants will receive ranibizumab 0.5 mg, by IVT injection, on Day 1 and Q4W, up to Week 44 for a total of 12 injections.

    Drug: Ranibizumab

Interventions

  • Vamikibart will be administered by IVT injection as specified in each treatment arm.

    Also known as: RO7200220

  • Ranibizumab 0.5 mg will be administered to the participants by IVT injection, as specified in the treatment arm.

    Also known as: Lucentis

  • OtherSham Procedure

    Sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. Sham procedure will be administered to participants in the Q8W arms at applicable visits to maintain masking between treatment arms.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Best-Corrected Visual Acuity (BCVA) Averaged Over Week 44 and Week 48, in Treatment-naïve Participants

    The BCVA, at a starting test distance of 4 meters (m), was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified early treatment diabetic retinopathy study \[ETDRS\] charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a Mixed Model for Repeated Measurements (MMRM) model. Adjusted mean has been reported.

    Time frame: Baseline, Weeks 44 and 48

Secondary outcomes

  1. Number of Participants With Systemic and Ocular Adverse Events (AEs)

    An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Systemic AEs include all non-ocular AEs. Only one eye was selected as the study eye, while the other was referred to as the fellow eye.

    Time frame: Up to Week 72

  2. Change From Baseline in BCVA Averaged Over Week 44 and Week 48, in Previously Treated Participants

    The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.

    Time frame: Baseline, Weeks 44 and 48

  3. Change From Baseline in BCVA Averaged Over Week 44 and Week 48, in Overall Enrolled Population

    The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.

    Time frame: Baseline, Weeks 44 and 48

  4. Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Treatment-naïve Participants

    The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.

    Time frame: Baseline, Weeks 32 and 36

  5. Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Previously Treated Participants

    The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.

    Time frame: Baseline, Weeks 32 and 36

  6. Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Overall Enrolled Population

    The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.

    Time frame: Baseline, Weeks 32 and 36

  7. Change From Baseline in BCVA Averaged Over Week 20 and Week 24, in Treatment-naïve Participants

    The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.

    Time frame: Baseline, Weeks 20 and 24

  8. Change From Baseline in BCVA Averaged Over Week 20 and Week 24, in Previously Treated Participants

    The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.

    Time frame: Baseline, Weeks 20 and 24

  9. Change From Baseline in BCVA Averaged Over Week 20 and Week 24, in Overall Enrolled Population

    The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.

    Time frame: Baseline, Weeks 20 and 24

  10. Change From Baseline in BCVA Over Time, in Overall Enrolled Population

    The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72

  11. Percentage of Participants Gaining Greater Than or Equal to (≥) 15, ≥ 10, ≥ 5, or ≥ 0 Letters in BCVA From Baseline Over Time, in Overall Enrolled Population

    The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. Percentages have been summarized.

    Time frame: From baseline up to Week 72

  12. Percentage of Participants Avoiding a Loss of ≥ 15, ≥ 10, or ≥ 5 Letters in BCVA From Baseline Over Time, in Overall Enrolled Population

    The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. Percentages have been summarized.

    Time frame: From baseline up to Week 72

  13. Percentage of Participants With BCVA ≥ 69 Letters (20/40 Snellen Equivalent) Over Time, in Overall Enrolled Population

    The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 (Snellen equivalent \<20/800) to 100 (Snellen equivalent of 20/10) letters. A gain in BCVA letter score from baseline indicates an improvement in visual acuity. Percentages have been summarized.

    Time frame: Baseline, Weeks 1, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

  14. Percentage of Participants With BCVA ≥ 84 Letters (20/20 Snellen Equivalent) Over Time, in Overall Enrolled Population

    The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 (Snellen equivalent \<20/800) to 100 (Snellen equivalent of 20/10) letters. A gain in BCVA letter score from baseline indicates an improvement in visual acuity. Percentages have been summarized.

    Time frame: Baseline, Weeks 1, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

  15. Percentage of Participants With BCVA of Less Than or Equal to (≤) 38 Letters (Snellen Equivalent 20/200) Over Time, in Overall Enrolled Population

    The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 (Snellen equivalent \<20/800) to 100 (Snellen equivalent of 20/10) letters. A gain in BCVA letter score from baseline indicates an improvement in visual acuity. Percentages have been summarized.

    Time frame: Baseline, Weeks 1, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

  16. Change From Baseline in Central Subfield Thickness (CST) Averaged Over Weeks 44 and 48, in Treatment-naïve Participants

    CST was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE), measured using Spectral Domain-Optical Coherence Tomography (SD-OCT). This analysis used a MMRM model. Adjusted mean has been reported.

    Time frame: Baseline, Weeks 44 and 48

  17. Change From Baseline in CST Averaged Over Weeks 44 and 48, in Previously Treated Participants

    CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.

    Time frame: Baseline, Weeks 44 and 48

  18. Change From Baseline in CST Averaged Over Weeks 44 and 48, in Overall Enrolled Population

    CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.

    Time frame: Baseline, Weeks 44 and 48

  19. Change From Baseline in CST Averaged Over Weeks 32 and 36, in Treatment-naïve Participants

    CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.

    Time frame: Baseline, Weeks 32 and 36

  20. Change From Baseline in CST Averaged Over Weeks 32 and 36, in Previously Treated Participants

    CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.

    Time frame: Baseline, Weeks 32 and 36

  21. Change From Baseline in CST Averaged Over Weeks 32 and 36, in Overall Enrolled Population

    CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.

    Time frame: Baseline, Weeks 32 and 36

  22. Change From Baseline in CST Averaged Over Weeks 20 and 24, in Treatment-naïve Participants

    CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.

    Time frame: Baseline, Weeks 20 and 24

  23. Change From Baseline in CST Averaged Over Weeks 20 and 24, in Previously Treated Participants

    CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.

    Time frame: Baseline, Weeks 20 and 24

  24. Change From Baseline in CST Averaged Over Weeks 20 and 24, in Overall Enrolled Population

    CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.

    Time frame: Baseline, Weeks 20 and 24

  25. Change From Baseline in CST Over Time, in Overall Enrolled Population

    CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72

  26. Percentage of Participants With Absence of DME Over Time, in Overall Enrolled Population

    Absence of DME was defined as CST \< 325 µm for spectralis SD-OCT, or \< 315 μm for cirrus SD-OCT or topcon SD-OCT. SD-OCT was performed on a Spectralis instrument. Percentages have been summarized.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72

  27. Percentage of Participants With Absence of Intraretinal Fluid (IRF) Over Time, in Overall Enrolled Population

    The absence of IRF in the study eye (defined as IRF absent or definite outside center subfield only) was assessed by the central reading center using SD-OCT. The percentage of participants with the absence of IRF at the foveal center were reported. Percentages have been summarized.

    Time frame: Baseline, Weeks 4, 12, 24, 36, 48, and 72

  28. Percentage of Participants With Absence of Subretinal Fluid (SRF) Over Time, in Overall ITT Population

    The absence of SRF in the study eye (defined as SRF absent or definite outside center subfield only) was assessed by the central reading center using SD-OCT. The percentage of participants with absence of SRF at the foveal center were reported. Percentages have been summarized.

    Time frame: Baseline, Weeks 4, 12, 24, 36, 48, and 72

07

Results

Posted May 11, 2026

Participant flow

A total of 394 participants with diabetic macular edema (DME) took part in the study at 74 investigative sites across Argentina, Canada, Czech Republic, Spain, Republic of Korea, Poland, the United Kingdom and the United States from 31 December 2021 to 21 April 2025.

Participant flow — Overall Study
MilestoneArm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4W
Started9510198100
Safety-evaluable population941009898
Treatment-naïve intent-to-treat (itt) population65656465
Previously treated itt population30363435
Completed57646484
Not completed38373416
Withdrew: Adverse event8993
Withdrew: Death1111
Withdrew: Lost to follow-up3143
Withdrew: Need for rescue treatment111010
Withdrew: Non-compliance with study drug0011
Withdrew: Reason not specified61162
Withdrew: Physician decision1240
Withdrew: Protocol violation2020
Withdrew: Withdrawal by subject6366

Outcome measures

SecondaryNumber of Participants With Systemic and Ocular Adverse Events (AEs)

An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Systemic AEs include all non-ocular AEs. Only one eye was selected as the study eye, while the other was referred to as the fellow eye.

Time frame:
Up to Week 72
Reported as:
Count of participants · Participants
Number of Participants With Systemic and Ocular Adverse Events (AEs)
ParticipantsArm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4W
Systemic AEs43585465
Ocular AEs in Study Eye39464131
Ocular AEs in Fellow Eye13252429
SecondaryChange From Baseline in BCVA Averaged Over Week 44 and Week 48, in Previously Treated Participants

The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.

Time frame:
Baseline, Weeks 44 and 48
Reported as:
Mean · ETDRS letters
Change From Baseline in BCVA Averaged Over Week 44 and Week 48, in Previously Treated Participants
ETDRS lettersArm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4W
Change From Baseline in BCVA Averaged Over Week 44 and Week 48, in Previously Treated Participants2.0 ± 2.74-0.5 ± 2.39-0.4 ± 2.499.6 ± 2.21
Statistical analysis
  • Arm A: Vamikibart 0.25 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = 0.0340 · Difference in adjusted means: -7.6 · 90% CI -13.4 to -1.7
  • Arm B: Vamikibart 1 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = 0.0027 · Difference in adjusted means: -10.1 · 90% CI -15.5 to -4.7
  • Arm C: Vamikibart 1 mg Q4W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = 0.0036 · Difference in adjusted means: -10.0 · 90% CI -15.5 to -4.4
SecondaryChange From Baseline in BCVA Averaged Over Week 44 and Week 48, in Overall Enrolled Population

The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.

Time frame:
Baseline, Weeks 44 and 48
Reported as:
Mean · ETDRS letters
Change From Baseline in BCVA Averaged Over Week 44 and Week 48, in Overall Enrolled Population
ETDRS lettersArm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4W
Change From Baseline in BCVA Averaged Over Week 44 and Week 48, in Overall Enrolled Population5.2 ± 1.193.3 ± 1.133.8 ± 1.1611.7 ± 1.09
Statistical analysis
  • Arm A: Vamikibart 0.25 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: -6.5 · 90% CI -9.2 to -3.8
  • Arm B: Vamikibart 1 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: -8.4 · 90% CI -11.0 to -5.8
  • Arm C: Vamikibart 1 mg Q4W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: -7.9 · 90% CI -10.5 to -5.2
SecondaryChange From Baseline in BCVA Averaged Over Week 32 and Week 36, in Treatment-naïve Participants

The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.

Time frame:
Baseline, Weeks 32 and 36
Reported as:
Mean · ETDRS letters
Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Treatment-naïve Participants
ETDRS lettersArm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4W
Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Treatment-naïve Participants5.8 ± 1.243.4 ± 1.235.8 ± 1.2613.0 ± 1.23
Statistical analysis
  • Arm A: Vamikibart 0.25 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: -7.2 · 90% CI -10.1 to -4.3
  • Arm B: Vamikibart 1 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: -9.5 · 90% CI -12.4 to -6.7
  • Arm C: Vamikibart 1 mg Q4W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: -7.2 · 90% CI -10.1 to -4.3
SecondaryChange From Baseline in BCVA Averaged Over Week 32 and Week 36, in Previously Treated Participants

The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.

Time frame:
Baseline, Weeks 32 and 36
Reported as:
Mean · ETDRS letters
Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Previously Treated Participants
ETDRS lettersArm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4W
Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Previously Treated Participants2.0 ± 1.313.4 ± 1.144.4 ± 1.208.5 ± 1.12
Statistical analysis
  • Arm A: Vamikibart 0.25 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = 0.0003 · Difference in adjusted means: -6.5 · 90% CI -9.4 to -3.6
  • Arm B: Vamikibart 1 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = 0.0022 · Difference in adjusted means: -5.0 · 90% CI -7.7 to -2.4
  • Arm C: Vamikibart 1 mg Q4W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = 0.0141 · Difference in adjusted means: -4.1 · 90% CI -6.8 to -1.4
SecondaryChange From Baseline in BCVA Averaged Over Week 32 and Week 36, in Overall Enrolled Population

The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.

Time frame:
Baseline, Weeks 32 and 36
Reported as:
Mean · ETDRS letters
Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Overall Enrolled Population
ETDRS lettersArm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4W
Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Overall Enrolled Population4.4 ± 0.933.6 ± 0.885.5 ± 0.9111.4 ± 0.88
Statistical analysis
  • Arm A: Vamikibart 0.25 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: -7.0 · 90% CI -9.1 to -4.9
  • Arm B: Vamikibart 1 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: -7.8 · 90% CI -9.9 to -5.8
  • Arm C: Vamikibart 1 mg Q4W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: -5.9 · 90% CI -8.0 to -3.8
SecondaryChange From Baseline in BCVA Averaged Over Week 20 and Week 24, in Treatment-naïve Participants

The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.

Time frame:
Baseline, Weeks 20 and 24
Reported as:
Mean · ETDRS letters
Change From Baseline in BCVA Averaged Over Week 20 and Week 24, in Treatment-naïve Participants
ETDRS lettersArm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4W
Change From Baseline in BCVA Averaged Over Week 20 and Week 24, in Treatment-naïve Participants6.4 ± 1.193.5 ± 1.185.3 ± 1.2011.1 ± 1.19
Statistical analysis
  • Arm A: Vamikibart 0.25 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = 0.0051 · Difference in adjusted means: -4.8 · 90% CI -7.6 to -2.0
  • Arm B: Vamikibart 1 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: -7.6 · 90% CI -10.4 to -4.8
  • Arm C: Vamikibart 1 mg Q4W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = 0.0006 · Difference in adjusted means: -5.9 · 90% CI -8.6 to -3.1
SecondaryChange From Baseline in BCVA Averaged Over Week 20 and Week 24, in Previously Treated Participants

The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.

Time frame:
Baseline, Weeks 20 and 24
Reported as:
Mean · ETDRS letters
Change From Baseline in BCVA Averaged Over Week 20 and Week 24, in Previously Treated Participants
ETDRS lettersArm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4W
Change From Baseline in BCVA Averaged Over Week 20 and Week 24, in Previously Treated Participants2.7 ± 1.362.8 ± 1.195.4 ± 1.228.4 ± 1.18
Statistical analysis
  • Arm A: Vamikibart 0.25 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = 0.0020 · Difference in adjusted means: -5.7 · 90% CI -8.7 to -2.7
  • Arm B: Vamikibart 1 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = 0.0012 · Difference in adjusted means: -5.6 · 90% CI -8.4 to -2.8
  • Arm C: Vamikibart 1 mg Q4W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = 0.0796 · Difference in adjusted means: -3.0 · 90% CI -5.8 to -0.2
SecondaryChange From Baseline in BCVA Averaged Over Week 20 and Week 24, in Overall Enrolled Population

The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.

Time frame:
Baseline, Weeks 20 and 24
Reported as:
Mean · ETDRS letters
Change From Baseline in BCVA Averaged Over Week 20 and Week 24, in Overall Enrolled Population
ETDRS lettersArm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4W
Change From Baseline in BCVA Averaged Over Week 20 and Week 24, in Overall Enrolled Population5.1 ± 0.923.3 ± 0.875.4 ± 0.8910.2 ± 0.88
Statistical analysis
  • Arm A: Vamikibart 0.25 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: -5.1 · 90% CI -7.2 to -3.0
  • Arm B: Vamikibart 1 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: -6.9 · 90% CI -8.9 to -4.8
  • Arm C: Vamikibart 1 mg Q4W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = 0.0002 · Difference in adjusted means: -4.8 · 90% CI -6.8 to -2.7
SecondaryChange From Baseline in BCVA Over Time, in Overall Enrolled Population

The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72
Reported as:
Mean · ETDRS letters
Change From Baseline in BCVA Over Time, in Overall Enrolled Population
ETDRS lettersArm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4W
Change at Week 43.0 ± 0.652.3 ± 0.633.8 ± 0.646.2 ± 0.63
Change at Week 84.3 ± 0.683.3 ± 0.655.1 ± 0.667.6 ± 0.66
Change at Week 124.4 ± 0.874.2 ± 0.824.6 ± 0.848.2 ± 0.83
Change at Week 164.5 ± 0.853.7 ± 0.815.0 ± 0.839.1 ± 0.83
Change at Week 205.2 ± 0.983.5 ± 0.925.0 ± 0.9510.2 ± 0.93
Change at Week 245.0 ± 0.933.2 ± 0.885.9 ± 0.9010.3 ± 0.89
Change at Week 284.6 ± 0.953.1 ± 0.905.3 ± 0.9310.6 ± 0.91
Change at Week 324.5 ± 0.953.4 ± 0.905.8 ± 0.9411.3 ± 0.90
Change at Week 364.2 ± 0.983.6 ± 0.925.2 ± 0.9611.4 ± 0.92
Change at Week 404.7 ± 1.252.3 ± 1.194.5 ± 1.2211.8 ± 1.14
Change at Week 445.3 ± 1.223.5 ± 1.164.3 ± 1.1911.7 ± 1.12
Change at Week 484.9 ± 1.222.9 ± 1.163.2 ± 1.1911.5 ± 1.11
Change at Week 524.8 ± 1.114.1 ± 1.054.7 ± 1.0710.4 ± 1.01
Change at Week 564.3 ± 1.342.5 ± 1.264.1 ± 1.309.8 ± 1.20
Change at Week 604.3 ± 1.413.5 ± 1.323.3 ± 1.378.8 ± 1.25
Change at Week 644.8 ± 1.453.7 ± 1.352.4 ± 1.409.2 ± 1.30
Change at Week 685.6 ± 1.364.2 ± 1.282.9 ± 1.329.7 ± 1.22
Change at Week 724.5 ± 1.393.6 ± 1.292.9 ± 1.359.2 ± 1.24
SecondaryPercentage of Participants Gaining Greater Than or Equal to (≥) 15, ≥ 10, ≥ 5, or ≥ 0 Letters in BCVA From Baseline Over Time, in Overall Enrolled Population

The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. Percentages have been summarized.

Time frame:
From baseline up to Week 72
Reported as:
Number · percentage of participants
Percentage of Participants Gaining Greater Than or Equal to (≥) 15, ≥ 10, ≥ 5, or ≥ 0 Letters in BCVA From Baseline Over Time, in Overall Enrolled Population
percentage of participantsArm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4W
Participants gaining ≥ 0 Letters97.998.099.0100
Participants gaining ≥ 5 Letters79.883.076.594.9
Participants gaining ≥ 10 Letters51.160.056.175.5
Participants gaining ≥ 15 Letters26.628.034.758.2
SecondaryPercentage of Participants Avoiding a Loss of ≥ 15, ≥ 10, or ≥ 5 Letters in BCVA From Baseline Over Time, in Overall Enrolled Population

The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. Percentages have been summarized.

Time frame:
From baseline up to Week 72
Reported as:
Number · percentage of participants
Percentage of Participants Avoiding a Loss of ≥ 15, ≥ 10, or ≥ 5 Letters in BCVA From Baseline Over Time, in Overall Enrolled Population
percentage of participantsArm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4W
Participants avoiding a loss of ≥ 5 Letters70.261.064.383.7
Participants avoiding a loss of ≥ 10 Letters85.180.087.893.9
Participants avoiding a loss of ≥ 15 Letters92.687.089.895.9
SecondaryPercentage of Participants With BCVA ≥ 69 Letters (20/40 Snellen Equivalent) Over Time, in Overall Enrolled Population

The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 (Snellen equivalent \<20/800) to 100 (Snellen equivalent of 20/10) letters. A gain in BCVA letter score from baseline indicates an improvement in visual acuity. Percentages have been summarized.

Time frame:
Baseline, Weeks 1, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Reported as:
Number · percentage of participants
Percentage of Participants With BCVA ≥ 69 Letters (20/40 Snellen Equivalent) Over Time, in Overall Enrolled Population
percentage of participantsArm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4W
Baseline34.732.743.935.0
Week 145.644.353.753.6
Week 450.649.555.365.6
Week 856.546.963.373.1
Week 1259.051.063.278.3
Week 1657.852.261.877.3
Week 2062.850.561.479.1
Week 2464.552.965.083.5
Week 2863.552.968.977.4
Week 3271.051.967.281.6
Week 3665.253.866.784.3
Week 4064.657.172.181.7
Week 4468.862.069.784.0
Week 4867.862.757.684.3
Week 5266.061.365.675.6
Week 5678.760.073.677.6
Week 6067.458.276.080.6
Week 6475.657.472.983.3
Week 6870.058.365.984.9
Week 7267.666.074.483.0
SecondaryPercentage of Participants With BCVA ≥ 84 Letters (20/20 Snellen Equivalent) Over Time, in Overall Enrolled Population

The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 (Snellen equivalent \<20/800) to 100 (Snellen equivalent of 20/10) letters. A gain in BCVA letter score from baseline indicates an improvement in visual acuity. Percentages have been summarized.

Time frame:
Baseline, Weeks 1, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Reported as:
Number · percentage of participants
Percentage of Participants With BCVA ≥ 84 Letters (20/20 Snellen Equivalent) Over Time, in Overall Enrolled Population
percentage of participantsArm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4W
Baseline1.11.001.0
Week 12.2006.2
Week 44.504.33.1
Week 83.55.25.65.4
Week 126.42.18.06.5
Week 167.23.311.29.1
Week 205.17.712.014.3
Week 247.94.712.515.3
Week 285.47.18.114.3
Week 3210.18.910.420.7
Week 365.810.08.715.7
Week 407.710.011.819.5
Week 4412.512.712.121.0
Week 486.89.012.116.9
Week 525.714.517.219.5
Week 5610.611.718.918.4
Week 6013.012.718.020.9
Week 6417.111.118.822.2
Week 6815.012.515.926.4
Week 7213.512.817.925.5
SecondaryPercentage of Participants With BCVA of Less Than or Equal to (≤) 38 Letters (Snellen Equivalent 20/200) Over Time, in Overall Enrolled Population

The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 (Snellen equivalent \<20/800) to 100 (Snellen equivalent of 20/10) letters. A gain in BCVA letter score from baseline indicates an improvement in visual acuity. Percentages have been summarized.

Time frame:
Baseline, Weeks 1, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Reported as:
Number · percentage of participants
Percentage of Participants With BCVA of Less Than or Equal to (≤) 38 Letters (Snellen Equivalent 20/200) Over Time, in Overall Enrolled Population
percentage of participantsArm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4W
Baseline1.11.01.01.0
Week 12.23.11.10
Week 41.12.11.10
Week 81.21.000
Week 121.31.01.10
Week 161.21.12.21.1
Week 201.33.33.60
Week 241.32.41.30
Week 2802.41.40
Week 3201.31.50
Week 3601.32.90
Week 4001.44.40
Week 44003.00
Week 481.71.53.00
Week 523.801.60
Week 5601.73.80
Week 6001.84.00
Week 6401.94.20
Week 6802.12.30
Week 7202.15.10
SecondaryChange From Baseline in Central Subfield Thickness (CST) Averaged Over Weeks 44 and 48, in Treatment-naïve Participants

CST was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE), measured using Spectral Domain-Optical Coherence Tomography (SD-OCT). This analysis used a MMRM model. Adjusted mean has been reported.

Time frame:
Baseline, Weeks 44 and 48
Reported as:
Mean · micrometers (µm)
Change From Baseline in Central Subfield Thickness (CST) Averaged Over Weeks 44 and 48, in Treatment-naïve Participants
micrometers (µm)Arm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4W
Change From Baseline in Central Subfield Thickness (CST) Averaged Over Weeks 44 and 48, in Treatment-naïve Participants-68.4 ± 14.23-50.8 ± 14.18-67.5 ± 14.44-174.2 ± 13.95
Statistical analysis
  • Arm A: Vamikibart 0.25 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: 105.8 · 90% CI 72.8 to 138.7
  • Arm B: Vamikibart 1 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: 123.3 · 90% CI 90.5 to 156.2
  • Arm C: Vamikibart 1 mg Q4W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: 106.7 · 90% CI 73.5 to 139.9
SecondaryChange From Baseline in CST Averaged Over Weeks 44 and 48, in Previously Treated Participants

CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.

Time frame:
Baseline, Weeks 44 and 48
Reported as:
Mean · µm
Change From Baseline in CST Averaged Over Weeks 44 and 48, in Previously Treated Participants
µmArm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4W
Change From Baseline in CST Averaged Over Weeks 44 and 48, in Previously Treated Participants-40.9 ± 22.14-81.4 ± 19.39-75.8 ± 20.44-185.7 ± 18.54
Statistical analysis
  • Arm A: Vamikibart 0.25 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: 144.8 · 90% CI 96.8 to 192.8
  • Arm B: Vamikibart 1 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = 0.0002 · Difference in adjusted means: 104.3 · 90% CI 59.7 to 148.9
  • Arm C: Vamikibart 1 mg Q4W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = 0.0001 · Difference in adjusted means: 109.9 · 90% CI 64.0 to 155.8
SecondaryChange From Baseline in CST Averaged Over Weeks 44 and 48, in Overall Enrolled Population

CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.

Time frame:
Baseline, Weeks 44 and 48
Reported as:
Mean · µm
Change From Baseline in CST Averaged Over Weeks 44 and 48, in Overall Enrolled Population
µmArm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4W
Change From Baseline in CST Averaged Over Weeks 44 and 48, in Overall Enrolled Population-57.3 ± 12.14-61.1 ± 11.64-70.5 ± 11.97-176.9 ± 11.32
Statistical analysis
  • Arm A: Vamikibart 0.25 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: 119.7 · 90% CI 92.3 to 147.1
  • Arm B: Vamikibart 1 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: 115.8 · 90% CI 89.1 to 142.6
  • Arm C: Vamikibart 1 mg Q4W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: 106.4 · 90% CI 79.3 to 133.6
SecondaryChange From Baseline in CST Averaged Over Weeks 32 and 36, in Treatment-naïve Participants

CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.

Time frame:
Baseline, Weeks 32 and 36
Reported as:
Mean · µm
Change From Baseline in CST Averaged Over Weeks 32 and 36, in Treatment-naïve Participants
µmArm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4W
Change From Baseline in CST Averaged Over Weeks 32 and 36, in Treatment-naïve Participants-57.1 ± 14.02-46.9 ± 13.94-64.8 ± 14.22-163.9 ± 13.87
Statistical analysis
  • Arm A: Vamikibart 0.25 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: 106.7 · 90% CI 74.2 to 139.3
  • Arm B: Vamikibart 1 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: 117.0 · 90% CI 84.5 to 149.5
  • Arm C: Vamikibart 1 mg Q4W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: 99.1 · 90% CI 66.3 to 131.9
SecondaryChange From Baseline in CST Averaged Over Weeks 32 and 36, in Previously Treated Participants

CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.

Time frame:
Baseline, Weeks 32 and 36
Reported as:
Mean · µm
Change From Baseline in CST Averaged Over Weeks 32 and 36, in Previously Treated Participants
µmArm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4W
Change From Baseline in CST Averaged Over Weeks 32 and 36, in Previously Treated Participants-35.4 ± 19.87-90.5 ± 17.45-81.5 ± 18.34-168.5 ± 17.10
Statistical analysis
  • Arm A: Vamikibart 0.25 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: 133.1 · 90% CI 89.5 to 176.7
  • Arm B: Vamikibart 1 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = 0.0020 · Difference in adjusted means: 78.0 · 90% CI 37.3 to 118.6
  • Arm C: Vamikibart 1 mg Q4W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = 0.0008 · Difference in adjusted means: 87.0 · 90% CI 45.3 to 128.8
SecondaryChange From Baseline in CST Averaged Over Weeks 32 and 36, in Overall Enrolled Population

CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.

Time frame:
Baseline, Weeks 32 and 36
Reported as:
Mean · µm
Change From Baseline in CST Averaged Over Weeks 32 and 36, in Overall Enrolled Population
µmArm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4W
Change From Baseline in CST Averaged Over Weeks 32 and 36, in Overall Enrolled Population-47.6 ± 11.57-62.1 ± 11.09-69.4 ± 11.41-164.8 ± 10.95
Statistical analysis
  • Arm A: Vamikibart 0.25 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: 117.2 · 90% CI 90.9 to 143.5
  • Arm B: Vamikibart 1 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: 102.6 · 90% CI 76.9 to 128.3
  • Arm C: Vamikibart 1 mg Q4W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: 95.3 · 90% CI 69.2 to 121.4
SecondaryChange From Baseline in CST Averaged Over Weeks 20 and 24, in Treatment-naïve Participants

CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.

Time frame:
Baseline, Weeks 20 and 24
Reported as:
Mean · µm
Change From Baseline in CST Averaged Over Weeks 20 and 24, in Treatment-naïve Participants
µmArm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4W
Change From Baseline in CST Averaged Over Weeks 20 and 24, in Treatment-naïve Participants-48.5 ± 11.61-68.8 ± 11.53-68.5 ± 11.62-150.4 ± 11.56
Statistical analysis
  • Arm A: Vamikibart 0.25 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: 101.9 · 90% CI 74.9 to 129.0
  • Arm B: Vamikibart 1 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: 81.5 · 90% CI 54.6 to 108.5
  • Arm C: Vamikibart 1 mg Q4W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: 81.9 · 90% CI 54.8 to 109.0
SecondaryChange From Baseline in CST Averaged Over Weeks 20 and 24, in Previously Treated Participants

CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.

Time frame:
Baseline, Weeks 20 and 24
Reported as:
Mean · µm
Change From Baseline in CST Averaged Over Weeks 20 and 24, in Previously Treated Participants
µmArm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4W
Change From Baseline in CST Averaged Over Weeks 20 and 24, in Previously Treated Participants-5.7 ± 20.88-81.7 ± 18.67-68.7 ± 19.22-146.4 ± 18.47
Statistical analysis
  • Arm A: Vamikibart 0.25 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: 140.6 · 90% CI 94.3 to 186.9
  • Arm B: Vamikibart 1 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = 0.0157 · Difference in adjusted means: 64.6 · 90% CI 21.0 to 108.2
  • Arm C: Vamikibart 1 mg Q4W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = 0.0045 · Difference in adjusted means: 77.7 · 90% CI 33.4 to 122.0
SecondaryChange From Baseline in CST Averaged Over Weeks 20 and 24, in Overall Enrolled Population

CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.

Time frame:
Baseline, Weeks 20 and 24
Reported as:
Mean · µm
Change From Baseline in CST Averaged Over Weeks 20 and 24, in Overall Enrolled Population
µmArm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4W
Change From Baseline in CST Averaged Over Weeks 20 and 24, in Overall Enrolled Population-36.1 ± 10.28-72.9 ± 9.88-69.0 ± 10.01-148.1 ± 9.86
Statistical analysis
  • Arm A: Vamikibart 0.25 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: 112.0 · 90% CI 88.5 to 135.5
  • Arm B: Vamikibart 1 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: 75.2 · 90% CI 52.1 to 98.2
  • Arm C: Vamikibart 1 mg Q4W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: 79.1 · 90% CI 55.9 to 102.3
SecondaryChange From Baseline in CST Over Time, in Overall Enrolled Population

CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72
Reported as:
Mean · µm
Change From Baseline in CST Over Time, in Overall Enrolled Population
µmArm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4W
Change at Week 4-25.7 ± 8.06-26.6 ± 7.88-36.3 ± 7.93-106.9 ± 7.83
Change at Week 8-31.2 ± 9.02-34.0 ± 8.76-50.9 ± 8.87-130.7 ± 8.76
Change at Week 12-38.4 ± 9.66-52.9 ± 9.27-56.3 ± 9.41-131.4 ± 9.27
Change at Week 16-39.3 ± 10.43-55.0 ± 10.06-59.5 ± 10.16-138.8 ± 10.08
Change at Week 20-37.9 ± 10.88-71.5 ± 10.44-64.0 ± 10.59-139.9 ± 10.41
Change at Week 24-30.7 ± 10.73-71.4 ± 10.31-69.7 ± 10.46-152.4 ± 10.27
Change at Week 28-47.3 ± 11.36-66.7 ± 10.87-67.3 ± 11.14-158.9 ± 10.81
Change at Week 32-47.2 ± 11.82-59.6 ± 11.33-69.6 ± 11.66-159.2 ± 11.18
Change at Week 36-44.2 ± 12.07-61.6 ± 11.56-64.8 ± 11.93-166.8 ± 11.40
Change at Week 40-50.3 ± 12.51-56.1 ± 12.03-69.7 ± 12.34-164.2 ± 11.74
Change at Week 44-53.5 ± 12.26-56.4 ± 11.75-73.6 ± 12.11-174.4 ± 11.44
Change at Week 48-58.4 ± 12.76-62.2 ± 12.24-63.1 ± 12.52-176.2 ± 11.82
Change at Week 52-63.4 ± 13.52-72.0 ± 12.89-89.6 ± 13.01-112.4 ± 11.92
Change at Week 56-67.6 ± 14.94-81.6 ± 13.84-74.6 ± 14.36-107.3 ± 12.66
Change at Week 60-73.9 ± 14.17-77.2 ± 13.41-81.5 ± 13.69-111.0 ± 12.34
Change at Week 64-66.1 ± 14.20-66.3 ± 13.31-81.1 ± 13.65-112.5 ± 12.48
Change at Week 68-73.2 ± 14.64-88.8 ± 13.81-65.4 ± 14.13-115.2 ± 12.87
Change at Week 72-73.9 ± 14.28-81.9 ± 13.45-78.8 ± 13.83-113.1 ± 12.61
SecondaryPercentage of Participants With Absence of DME Over Time, in Overall Enrolled Population

Absence of DME was defined as CST \< 325 µm for spectralis SD-OCT, or \< 315 μm for cirrus SD-OCT or topcon SD-OCT. SD-OCT was performed on a Spectralis instrument. Percentages have been summarized.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72
Reported as:
Number · percentage of participants
Percentage of Participants With Absence of DME Over Time, in Overall Enrolled Population
percentage of participantsArm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4W
Baseline3.2 (0.0 to 6.7)1.0 (0.0 to 3.0)4.1 (0.2 to 8.1)6.0 (1.3 to 10.7)
Week 46.8 (1.6 to 12.1)8.4 (2.8 to 14.0)13.8 (6.9 to 20.8)35.4 (25.8 to 45.0)
Week 810.6 (4.0 to 17.1)12.5 (5.9 to 19.1)17.8 (9.9 to 25.7)53.3 (43.1 to 63.5)
Week 128.9 (2.6 to 15.1)18.9 (11.1 to 26.8)24.1 (15.1 to 33.1)53.3 (43.1 to 63.5)
Week 1612.0 (5.0 to 19.1)16.3 (8.8 to 23.9)25.8 (16.7 to 34.9)61.4 (51.2 to 71.5)
Week 2019.2 (10.5 to 28.0)27.8 (18.5 to 37.0)30.1 (20.3 to 40.0)64.4 (54.6 to 74.3)
Week 2417.1 (8.6 to 25.6)25.9 (16.6 to 35.2)26.3 (16.6 to 35.9)70.6 (60.9 to 80.3)
Week 2824.7 (14.8 to 34.5)29.4 (19.7 to 39.1)33.8 (23.0 to 44.6)73.8 (64.4 to 83.2)
Week 3235.7 (24.5 to 46.9)28.8 (18.8 to 38.7)34.3 (23.0 to 45.7)75.9 (66.9 to 84.9)
Week 3630.0 (19.3 to 40.7)31.3 (21.1 to 41.4)35.3 (23.9 to 46.7)79.5 (70.8 to 88.2)
Week 4033.3 (22.0 to 44.7)27.1 (16.7 to 37.6)35.3 (23.9 to 46.7)78.0 (69.1 to 87.0)
Week 4434.4 (22.7 to 46.0)33.8 (22.8 to 44.8)35.4 (23.8 to 47.0)80.2 (71.6 to 88.9)
Week 4841.7 (29.2 to 54.1)35.8 (24.3 to 47.3)30.8 (19.5 to 42.0)79.5 (70.8 to 88.2)
Week 5235.8 (22.9 to 48.8)39.3 (27.1 to 51.6)36.5 (24.6 to 48.4)54.9 (44.1 to 65.6)
Week 5636.2 (22.4 to 49.9)41.7 (29.2 to 54.1)45.3 (31.9 to 58.7)59.7 (48.8 to 70.7)
Week 6047.8 (33.4 to 62.3)41.8 (28.8 to 54.9)50.0 (36.1 to 63.9)61.2 (49.5 to 72.9)
Week 6448.8 (33.5 to 64.1)48.1 (34.8 to 61.5)47.9 (33.8 to 62.0)61.8 (49.0 to 74.7)
Week 6845.0 (29.6 to 60.4)51.1 (36.8 to 65.4)48.8 (33.9 to 63.8)62.3 (49.2 to 75.3)
Week 7243.2 (27.3 to 59.2)42.6 (28.4 to 56.7)48.7 (33.0 to 64.4)60.9 (46.8 to 75.0)
SecondaryPercentage of Participants With Absence of Intraretinal Fluid (IRF) Over Time, in Overall Enrolled Population

The absence of IRF in the study eye (defined as IRF absent or definite outside center subfield only) was assessed by the central reading center using SD-OCT. The percentage of participants with the absence of IRF at the foveal center were reported. Percentages have been summarized.

Time frame:
Baseline, Weeks 4, 12, 24, 36, 48, and 72
Reported as:
Number · percentage of participants
Percentage of Participants With Absence of Intraretinal Fluid (IRF) Over Time, in Overall Enrolled Population
percentage of participantsArm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4W
Baseline22.115.224.725.0
Week 421.626.632.346.9
Week 1233.840.038.156.0
Week 2434.745.253.864.3
Week 3642.443.643.984.0
Week 4849.247.844.477.8
Week 7262.255.361.576.1
SecondaryPercentage of Participants With Absence of Subretinal Fluid (SRF) Over Time, in Overall ITT Population

The absence of SRF in the study eye (defined as SRF absent or definite outside center subfield only) was assessed by the central reading center using SD-OCT. The percentage of participants with absence of SRF at the foveal center were reported. Percentages have been summarized.

Time frame:
Baseline, Weeks 4, 12, 24, 36, 48, and 72
Reported as:
Number · percentage of participants
Percentage of Participants With Absence of Subretinal Fluid (SRF) Over Time, in Overall ITT Population
percentage of participantsArm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4W
Baseline62.161.668.067.0
Week 470.571.682.885.4
Week 1281.877.987.196.7
Week 2484.089.388.697.6
Week 3687.989.793.9100
Week 4889.891.093.798.8
Week 7294.693.697.495.7
PrimaryChange From Baseline in Best-Corrected Visual Acuity (BCVA) Averaged Over Week 44 and Week 48, in Treatment-naïve Participants

The BCVA, at a starting test distance of 4 meters (m), was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified early treatment diabetic retinopathy study \[ETDRS\] charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a Mixed Model for Repeated Measurements (MMRM) model. Adjusted mean has been reported.

Time frame:
Baseline, Weeks 44 and 48
Reported as:
Mean · ETDRS letters
Change From Baseline in Best-Corrected Visual Acuity (BCVA) Averaged Over Week 44 and Week 48, in Treatment-naïve Participants
ETDRS lettersArm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4W
Change From Baseline in Best-Corrected Visual Acuity (BCVA) Averaged Over Week 44 and Week 48, in Treatment-naïve Participants7.1 ± 1.284.6 ± 1.265.5 ± 1.2913.0 ± 1.26
Statistical analysis
  • Arm A: Vamikibart 0.25 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = 0.0012 · Difference in adjusted means: -5.9 · 90% CI -8.9 to -3.0
  • Arm B: Vamikibart 1 mg Q8W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: -8.4 · 90% CI -11.3 to -5.4
  • Arm C: Vamikibart 1 mg Q4W vs Arm D: Ranibizumab 0.5 mg Q4W · MMRM · p = <0.0001 · Difference in adjusted means: -7.5 · 90% CI -10.5 to -4.5

Adverse events

Collected over From baseline up to 72 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Vamikibart 0.25 mg Q8W1/94 (1.1%)17/94 (18.1%)25/94 (26.6%)
Arm B: Vamikibart 1 mg Q8W1/100 (1%)25/100 (25%)40/100 (40%)
Arm C: Vamikibart 1 mg Q4W1/98 (1%)21/98 (21.4%)36/98 (36.7%)
Arm D: Ranibizumab 0.5 mg Q4W1/98 (1%)20/98 (20.4%)32/98 (32.7%)
Most frequent serious events
Showing 10 of 77
Most frequent serious events
EventArm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4W
PneumoniaInfections and infestations0/944/1001/981/98
UveitisEye disorders0/941/1003/980/98
Cerebrovascular accidentNervous system disorders0/942/1003/980/98
Vitreous haemorrhageEye disorders0/943/1001/982/98
Myocardial infarctionCardiac disorders2/940/1000/980/98
Retinal occlusive vasculitisEye disorders0/940/1002/980/98
Urinary tract infectionInfections and infestations0/942/1000/982/98
Chronic kidney diseaseRenal and urinary disorders0/941/1002/980/98
End stage renal diseaseRenal and urinary disorders0/940/1002/980/98
AsthmaRespiratory, thoracic and mediastinal disorders0/940/1000/982/98
Most frequent other events
Most frequent other events
EventArm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4W
Diabetic retinal oedemaEye disorders7/9410/10012/985/98
Conjunctival haemorrhageEye disorders6/9410/1006/986/98
CataractEye disorders1/947/1005/989/98
HypertensionVascular disorders6/948/1005/987/98
Vitreous haemorrhageEye disorders3/946/1006/984/98
COVID-19Infections and infestations2/946/1003/984/98
Diabetic retinopathyEye disorders5/942/1004/982/98
NasopharyngitisInfections and infestations2/942/1004/985/98

Baseline characteristics

Overall intent-to-treat (ITT) population included all randomized participants. Participants were grouped according to the treatment assigned at randomization.

Age, Continuous
Age, Continuous(years)Arm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4WTotal
Mean64.2 ± 9.863.2 ± 10.062.8 ± 8.759.8 ± 9.862.5 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4WTotal
Female51454345184
Male44565555210
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4WTotal
Hispanic or Latino151410847
Not Hispanic or Latino42475455198
Unknown or Not Reported38403437149
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: Vamikibart 0.25 mg Q8WArm B: Vamikibart 1 mg Q8WArm C: Vamikibart 1 mg Q4WArm D: Ranibizumab 0.5 mg Q4WTotal
American Indian or Alaska Native21104
Asian565622
Native Hawaiian or Other Pacific Islander00000
Black or African American1066628
White36454950180
More than one race00000
Unknown or Not Reported42433738160
08

Study locations

74 sites
  • Win Retina
    Arcadia, California 91006, United States
  • Retina Consultants, San Diego
    Poway, California 92064, United States
  • Retinal Consultants Med Group
    Sacramento, California 95825, United States
  • Bay Area Retina Associates
    Walnut Creek, California 94598, United States
  • Colorado Retina Associates, PC
    Lakewood, Colorado 80228, United States
  • Emerson Clinical Research Institute LLC
    Washington D.C., District of Columbia 20011-3010, United States
  • Rand Eye
    Deerfield Beach, Florida 33064, United States
  • National Ophthalmic Research Institute
    Fort Myers, Florida 33912, United States
  • Florida Retina Institute
    Orlando, Florida 32806-1101, United States
  • Retina Vitreous Associates of Florida
    St. Petersburg, Florida 33607, United States
  • Retina Specialists of Tampa
    Wesley Chapel, Florida 33544, United States
  • Butchertown Clinical Trials
    Louisville, Kentucky 40206, United States
  • Cumberland Valley Retina PC
    Hagerstown, Maryland 21740, United States
  • Deep Blue Retina PLLC
    Southaven, Mississippi 38671, United States
  • Sierra Eye Associates
    Reno, Nevada 89502, United States
  • Opthalmic Consultants of LI
    Lynbrook, New York 11563, United States
  • University of Rochester Flaum Eye Institute
    Rochester, New York 14642, United States
  • Western Carolina Retinal Associate PA
    Asheville, North Carolina 28803, United States
  • Wake Forest Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
  • Meridian Clinical Research
    Cincinnati, Ohio 45219, United States
  • Verum Research LLC
    Eugene, Oregon 97401, United States
  • EyeHealth Northwest
    Portland, Oregon 97225, United States
  • Erie Retinal Surgery
    Erie, Pennsylvania 16507, United States
  • Eye Care Specialists, PC
    Kingston, Pennsylvania 18704, United States
  • Sewickley Eye Group
    Sewickley, Pennsylvania 15143, United States
  • Charleston Neuroscience Institute
    Ladson, South Carolina 29456, United States
  • Black Hills Eye Institute
    Rapid City, South Dakota 57701, United States
  • Retina Consultants of Nashville
    Nashville, Tennessee 37203, United States
  • Texas Retina Associates
    Arlington, Texas 75075, United States
  • Austin Clinical Research LLC
    Austin, Texas 78750, United States
  • Retina Consultants of Texas
    Bellaire, Texas 77401, United States
  • Valley Retina Institute P.A.
    McAllen, Texas 78503, United States
  • Retina Consultants of Texas
    The Woodlands, Texas 78240, United States
  • Strategic Clinical Research Group, LLC
    Willow Park, Texas 76087, United States
  • Piedmont Eye Center
    Lynchburg, Virginia 24502, United States
  • Wagner Macula & Retina Center
    Norfolk, Virginia 23502, United States
  • Organizacion Medica de Investigacion
    Buenos Aires, C1015ABO, Argentina
  • Centro Oftalmologico Dr. Charles S.A.
    Capital Federal, C1116, Argentina
  • Oftalmos
    Capital Federal, C1120AAN, Argentina
  • Buenos Aires Mácula
    Ciudad Autonoma Buenos Aires, C1061AAE, Argentina
  • Centro Privado de Ojos Romagosa
    Córdoba, Argentina
  • Centro de ojos Loria
    Lomas de Zamora, Argentina
  • Oftar
    Mendoza, M5500GGK, Argentina
  • Microcirugía Ocular S.A
    Rosario, S2000CTC, Argentina
  • Grupo Laser Vision
    Rosario, S2000DLA, Argentina
  • Retina Institute of Ottawa
    Ottawa, Ontario K2B 7E9, Canada
  • Toronto Retina Institute
    Toronto, Ontario M3C 0G9, Canada
  • Institut De L'Oeil Des Laurentides
    Boisbriand, Quebec J7H 0E8, Canada
  • Faculty Hospital Ostrava
    Ostrava, 708 52, Czechia
  • Faculty Hospital Kralovske Vinohrady
    Prague, 100 34, Czechia
  • General Teaching Hospital Prague
    Prague, 128 08, Czechia
  • AXON Clinical
    Prague, Czechia
  • Niepubliczny Zak?ad Opieki Zdrowotnej PRYZMAT-OKULISTYKA
    Gliwice, 44-100, Poland
  • Uniwersyteckie Centrum Kliniczne
    Katowice, 40-514, Poland
  • Centrum Medyczne UNO-MED
    Krakow, 31-070, Poland
  • SPSK nr 1 w Lublinie
    Lublin, 20-079, Poland
  • Centrum Diagnostyki i Mikrochirurgii Oka LENS
    Olsztyn, 10-424, Poland
  • LensClinic
    Rybnik, 44-203, Poland
  • Caminomed
    Tarnowskie Góry, 42-600, Poland
  • Emanuelli Research and Development Center LLC
    Arecibo, 00612, Puerto Rico
  • Yeungnam University Medical Center
    Daegu, 42415, South Korea
  • Seoul National University Bundang Hospital
    Seongnam-si, 13605, South Korea
  • Asan Medical Center
    Seoul, 05505, South Korea
  • Samsung Medical Center
    Seoul, 06351, South Korea
  • Kim's Eye Hospital
    Seoul, 07301, South Korea
  • Hospital General de Catalunya
    Sant Cugat de Valles, Barcelona 08190, Spain
  • Hospital Universitario Puerta de Hierro
    Majadahonda, Madrid 28222, Spain
  • Oftalvist Valencia
    Burjassot, Valencia 46100, Spain
  • Hospital Universitario Miguel Servet
    Zaragoza, 50009, Spain
  • Bristol Eye Hospital
    Bristol, BS1 2LX, United Kingdom
  • Gloucestershire Hospitals NHS Foundation Trust
    Gloucestershire, GL1 3NN, United Kingdom
  • Royal Surrey County Hospital
    Guildford, GU2 7XX, United Kingdom
  • Moorfields Eye Hospital NHS Foundation Trust
    London, EC1V 2PD, United Kingdom
  • Royal Victoria Infirmary
    Newcastle upon Tyne, NE1 4LP, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Nov 2024, 34 months.

Results were first posted in May 2026, 1 year 6 months after primary completion. A results delay was requested in Oct 2025.

Of 32 industry-sponsored phase 2 interventional studies under Macular Edema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's 34 months is above that.

Counting every sponsor, half of 50 studies reached it within 19 months; a quarter within 15 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2021
First posted
Dec 9, 2021
StartActual
Dec 31, 2021
Primary completionActual
Nov 6, 2024
CompletionActual
Apr 21, 2025
Results delay requested
Oct 20, 2025
Results first posted
May 11, 2026
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05151731
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 9, 2021
Start date
Dec 31, 2021
Primary completion
Nov 6, 2024
Completion
Apr 21, 2025
Results posted
May 11, 2026
Last update
May 11, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vamikibart

Start the discussion